Klinikum Konstanz GmbH
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
At Klinikum Konstanz GmbH, respiratory research is a major focus, with studies in idiopathic pulmonary fibrosis, progressive pulmonary fibrosis, progressive fibrosing interstitial lung diseases, and bronchiectasis. These trials are designed to assess safety, preserve lung function, and test new treatments aimed at slowing disease progression and easing breathing-related complications.
- Idiopathic pulmonary fibrosis and related fibrotic lung diseases
- Bronchiectasis with chronic Pseudomonas aeruginosa colonization
- Evaluation of therapies that may reduce lung function decline
- Studies of long-term tolerability and respiratory symptom control
Overall, this area reflects strong interest in improving care for chronic and often progressive lung disorders.
Cardiovascular Diseases
The site also contributes to research in cardiovascular diseases, including hypertension, established cardiovascular disease, and high cardiovascular risk. These trials are focused on testing new approaches to lower risk, improve cholesterol management, and prevent major heart-related events.
- Hypertension and broader blood pressure control
- Established cardiovascular disease and prevention of complications
- Improving LDL cholesterol reduction
- Reducing the risk of heart attack, stroke, and heart failure events
This work supports better long-term prevention strategies for people with significant cardiovascular risk.
Neoplasms
Oncology research at Klinikum Konstanz GmbH spans non-small cell lung cancer, epithelial ovarian cancer, and intermediate-stage hepatocellular carcinoma. The studies are mainly aimed at evaluating treatment effectiveness, extending disease control, and improving outcomes after standard therapy or in newly diagnosed advanced disease.
- Advanced ovarian cancer and related gynecologic cancers
- EGFR-mutated non-squamous NSCLC
- Hepatocellular carcinoma in intermediate-stage disease
- Assessment of new treatment combinations and maintenance approaches
These trials highlight a broad effort to refine cancer care across solid tumors.
Nutritional and Metabolic Diseases
The metabolic research portfolio includes non-cirrhotic non-alcoholic steatohepatitis with fibrosis, hypercholesterolemia, and chronic kidney disease. The main purpose of these trials is to test therapies that may improve liver health, lower harmful cholesterol levels, and protect kidney and heart function over time.
- NASH with fibrosis and liver disease progression
- Hypercholesterolemia and lipid-lowering treatment
- Chronic kidney disease with cardiorenal protection goals
- Prevention of worsening organ damage in metabolic disease
This area shows a strong emphasis on reducing long-term complications linked to metabolic and kidney disorders.
Female Urogenital Diseases and Pregnancy Complications
Research in this therapeutic area centers on ovarian cancer and other advanced gynecologic malignancies, including peritoneal cancer and fallopian tube cancer. The trials are designed to evaluate maintenance strategies and combination treatments that may help delay disease progression after surgery and chemotherapy.
- Newly diagnosed advanced epithelial ovarian cancer
- Peritoneal and fallopian tube cancer
- Maintenance treatment after initial cancer therapy
- Improving progression-free survival in gynecologic oncology
These studies support ongoing efforts to improve outcomes for women with complex gynecologic cancers.
Reproductive and Urinary Physiological Phenomena
This research area overlaps with kidney and urinary health, with studies involving chronic kidney disease and broader cardiorenal protection. The trials are primarily aimed at understanding how new treatments may help preserve function and reduce the risk of serious complications affecting the kidneys and heart.
- Kidney function preservation in chronic disease
- Reducing hospitalization and cardiovascular complications
- Support for long-term organ protection strategies
- Research linking urinary and cardiovascular health
At this site, the focus is on practical treatment options that may slow decline and improve everyday health outcomes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 26 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 12 by active trials.
- 1Boehringer Ingelheim Espana S.A.2active
lock +11 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Boehringer Ingelheim Espana S.A.5trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikum Konstanz GmbH
lock Showing 1 of 18 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2a Study to Evaluate the Safety and Efficacy of ABBV-142 in Adults with Idiopathic Pulmonary Fibrosis | AbbVie Deutschland GmbH & Co. KG | Phase II | Recruiting | Jul 2026 | — |
IMP list
lock Showing 1 of 26 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| 1-[[(5R)-2-[4-(5-Chloro-2-Pyrimidinyl)-1-Piperidinyl]-6,7- Dihydro-5-Oxidothieno[3,2-D]Pyrimidin-4- Yl]Amino]-Cyclobutanemethanol | 3 | Unknown | 2022-10-05 | 2025-11-14 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.